EGFR and interstitial lung disease: Although we did not obtain the rechallenge recommendations of EGFR-TKI drug after almonertinib-induced ILD, most literatures confirm that when an EGFR-TKI is discontinued due to ILD, replacing other EGFR-TKI drugs can usually successfully control tumor progression (40–42).